{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-046572","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.598557+00:00","generated_at":"2026-06-10T23:34:20.496860+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PepGen reports preclinical data: PGN-EDODM1 corrects 99% of mis-splicing in DM1 mouse model","bullets":["EDO platform delivers 25-fold higher oligonucleotide to myotube nuclei vs naked in vitro.","72% of skeletal muscle nuclei in NHPs positive for oligo after two 30 mg/kg doses.","Single dose of PGN-EDODM1 reversed 76% myotonia and corrected 68% mis-splicing in DM1 mouse.","Four doses reversed 99% myotonia and corrected 99% mis-splicing; well-tolerated.","PGN-EDO51 safety in humans: transient, mild, reversible TEAEs at 5 and 10 mg/kg."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-046572","json":"https://secwatch.observer/filing/0000950170-23-046572.json","markdown":"https://secwatch.observer/filing/0000950170-23-046572.md","text":"https://secwatch.observer/filing/0000950170-23-046572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/0000950170-23-046572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023046572/pepg-20230906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:34:20.496860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}